Samsung Invests in C2N Diagnostics 

C2N Diagnostics LLC (C2N) has attracted a $10 million investment from Samsung (Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation), which will bolster its ability to further scale its clinical laboratory services and advanced brain health diagnostic solutions.

“Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has contributed to the stabilization of the biopharmaceutical supply chain and better access to high quality bio pharmaceutics,” Samsung C&T Corporation Executive Vice President Jaywoo Kim said. “The investment into C2N Diagnostics shows Samsung’s continued dedication to future growth in the Life Science sector by seeking new business opportunities based on intelligent analytics and uniquely special diagnostics technologies. We are confident that C2N Diagnostics will further grow its leading position in the industry by serving global biopharma customers as well as medical service providers with its well-established blood biomarker testing portfolio.”

Through this strategic investment, C2N aims to continue accelerating organizational capabilities to ensure patients globally have access to its blood biomarker testing technologies for Alzheimer’s disease and related dementias. Early and accurate diagnosis is of critical importance given personal, financial, and societal impacts of Alzheimer’s disease and related dementias.

The Journal of the American Medical Association (JAMA) recently published a large clinical study examining the ability of C2N’s PrecivityAD2 blood test algorithm to improve Alzheimer’s disease diagnostic accuracy in primary care settings, where most patients with cognitive concerns turn to for initial answers about their memory loss. The study found similar test performance robustness in patients who saw memory care specialists. The PrecivityAD2 test result delivered a highly statistically significant accuracy of more than 90% at a pre-defined, single binary cutoff compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis.

With more than 50,000 Precivity analytes reported and over 150 Neuro academic, clinical, and research collaborations globally using Precivity biomarkers, C2N has significantly impacted Alzheimer’s research, the company asserted. C2N is now expanding the biomarker pipeline by developing advanced assays targeting tau pathology, Parkinson’s disease research, and developing technologies to decentralize mass spectrometry testing.

“Samsung is widely recognized for the seriousness and thorough reviews it undertakes in its strategic decisions,” C2N CEO Dr. Joel Braunstein stated. “We greatly appreciate the confidence Samsung brings to this partnership as we believe it affirms the value and quality of our advanced diagnostic solutions. Samsung’s important investment will allow C2N to further strengthen our capabilities, expand our commercial scale, and innovate next generation diagnostic tests that can improve patients’ lives.”   

C2N is a specialty diagnostics provider of clinical laboratory services and advanced brain health diagnostic solutions. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in more than 150 Alzheimer’s disease and other research studies worldwide. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the Alzheimer’s disease trajectory. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums in addition to research and distribution partnerships with labs globally including Grupo Fleury, Healius, Mediford, Mayo Clinic Laboratories, and Unilabs. More than 50,000 Precivity-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.

The company acknowledges support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, and Alzheimer’s Association.

Samsung C&T Corporation, a player in various industries ranging from construction, trading, fashion and resorts, is expanding its portfolio with strategic investments in the biopharmaceutical and life sciences industry.